Trump administration will allow pharmacies to make popular peptides
The Trump administration has announced a new policy permitting pharmacies to manufacture certain peptides that have gained popularity in wellness circles, despite their unverified status and previous restrictions. The Department of Health and Human Services (HHS) is now opting for enforcement discretion regarding six specific peptides, effectively allowing small compounding pharmacies to produce them without facing penalties.
Health Secretary Robert F. Kennedy Jr. has expressed strong support for these peptides, mentioning that he has personally used some of them. Peptides are chains of amino acids that are shorter than proteins and can have significant physiological effects. While some peptides are naturally occurring, others are synthetic. Despite their promotion by wellness influencers and some clinicians for a variety of health claims, the scientific evidence supporting their safety and efficacy remains limited.
Although these peptides have not undergone the stringent review process of the Food and Drug Administration (FDA), the new policy may facilitate easier access for consumers. Nonetheless, the emphasis on smaller compounding pharmacies could present challenges in meeting the anticipated demand.
In July, an advisory panel to the FDA supported broader access to six peptides through compounding pharmacies. However, during the same meeting, FDA scientists advised against lifting existing restrictions on these substances.
The HHS's new policy characterizes compounding as a safer alternative to the illicit "research-use-only" peptides that are often sold online and sourced from questionable international suppliers. The six peptides in question and their purported uses include:
- BPC-157 for ulcerative colitis
- Epitalon for insomnia
- KPV for wound healing
- MOTS-c for metabolic health
- Semax for migraines
- TB-500 for wound healing
Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in Florida, noted that there has been considerable interest in these peptides over the years, but his company refrained from producing them due to their illegal status. The new policy does not alter the legal classification of these substances but provides a framework for small compounding pharmacies, known as 503A pharmacies, to manufacture them. This does not extend to larger facilities, called 503Bs, that produce medications in higher volumes.
Fritzler indicated that his smaller compounding facility will only be able to produce these peptides in limited quantities, which may not satisfy consumer demand. "We won't be able to meet demand," he stated, adding that Olympia might only be able to compound one of the six peptides initially as they prepare their facility. "I don't think all the [503]As in the country could meet the demand."
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed satisfaction with the administration's decision, highlighting that it provides a "more accountable alternative" for patients seeking these peptides from the gray market. He emphasized that this approach will integrate patients into a system that adheres to pharmacy standards, regulatory oversight, and serious adverse event reporting.
However, Brunner cautioned that it may take time for compounding pharmacies to begin dispensing these products, as ingredient suppliers must ensure compliance with the new policy's standards, and pharmacies need to verify this compliance as well.
Some consumer advocacy organizations have raised alarms about the potential risks to patients posed by this policy. Public Citizen, a nonprofit group, pointed out that Kennedy's decision appears to have been made unilaterally, bypassing the usual regulatory processes. Dr. Robert Steinbrook, director of the Health Research Group at Public Citizen, criticized the move, asserting that it undermines the FDA and jeopardizes public health. "All peptide substances should go through the standard FDA approval process for new drugs," he stated. "The HHS Secretary should support, not sabotage, needed FDA enforcement actions to protect consumers."
Steinbrook urged healthcare providers to inform their patients about the risks of contamination and other potential adverse effects associated with these unproven peptides. In addition, the Partnership for Safe Medicines, which comprises various pharmacy and pharmacist organizations, submitted a citizen petition last week requesting that the FDA disregard the July advisory committee's recommendation to permit the compounding of these peptides. Executive Director Shabbir Safda expressed concern that the administration's decision leaves consumers in a state of uncertainty regarding the safety of these substances, despite the FDA's own scientists advising against their approval due to insufficient evidence.